IS CELL DEATH IN PARKINSON’S DISEASE REALLY APOPTOSIS?
Ozansoy M, Basak AN*
*Corresponding Author: A. Nazli Basak, Bogaziçi University, Department of Molecular Biology and Genetics, 34342, Bebek, Istanbul, Turkey; Tel.: +90-212-359-66-79; Fax: +90-212-287-24-68; E-mail: basak@boun.edu.tr
page: 3

PROGRAMMED CELL DEATH/APOPTOSIS

Programmed cell death (PCD) plays a central role during prenatal development, especially in morphogenesis, sexual differentiation and the emergence of the immune and nervous systems. Programmed cell death in the adult allows tissue homeostasis, elimination of damaged or abnormal cells and defense against infections. Conversely, PCD dysregulation has been proposed to participate in the pathogenesis of cancer, autoimmunity, infectious disease and neurodegeneration [4].

      Terminology. Cell death processes have been succes­sively named “chromatolysis,” “pyknosis,” “karyolysis,” “shrinkage necrosis,” “programmed cell death,” “cell sui­cide,” “self-destruction” and “apoptosis”. Program means “pre-written” and suggests a framework of design and finality, and favors confusion between pre-written genetic information and the multiple ways used by the cells and the body. However, it is not the survival or death of each individual cell that is programmed, but each cell’s capacity to induce or repress its self-destruction. “Cell suicide” and “self-destruction” also have an anthropomorphic reference, and favor confusion between the act of initiating self-dis­mantling that the cell indeed performs by activating an intrinsic cell death mechanism, and both the decision to destroy itself and the implementation of the death process that depends on the nature of interactions between the cell and the body, rather than on the cell itself. Apoptosis (the “fall,” as that of leaves in autumn), while being perceived as describing the death process itself, actually describes the stereotyped modifications usually associated with PCD. These involve cell shrinkage, plasma membrane blebbing with increased permeability, mitochondrial outer membrane permeabilization, nuclear chromatin condensa­tion and fragmentation, nuclear DNA fragmentation, cyto­skeletal modifications and segmentation of the cell into apoptotic bodies. Also involved is expression of various death signaling molecules that allows neighboring cells to rapidly ingest the dying cell. Programmed cell death, in contrast with passive and chaotic necrotic death (that in­volves cell swelling, plasma membrane rupture and cell content spillage), usually induces no lesions in the organ and tissue in which it occurs.

      Since apoptosis is the most typical but not the only phenotype of self-destruction, the term “apoptosis” should not be considered as a synonym of “programmed cell death,” “cell suicide” and “self-destruction” [4].

      Apoptosis. In mammalian cells, the apoptosis is medi­ated through an intrinsic or an extrinsic pathway, depend­ing on the origin of the death stimuli.

      The intrinsic pathway is mediated by mitochondria, which, in response to apoptotic stimuli, release several proteins from their intermembrane space into the cytosol. These include cytochrome c, SMAC (second mitochon-dria-derived activator of caspases)/DIABLO (direct in­hibitor of apoptosis (IAP)-binding protein with low pI), EndoG (endonuclease G) and OMI/HTRA2 (high-tem-perature-requirement protein A2) [5-8]. Critical in progres­sion of apoptosis is the formation of a “mitochondrial permeability transition pore,” which is regulated and con­trolled by the interactions of pro-(Bax, Bim, Bid, Bak and Noxa) and anti-apoptotic proteins (Bcl-2, BclXL and Bcl-w) of the Bcl-2 family. After the formation of permeability transition pore in the outer membrane of mitochondria, the above-mentioned proteins are released into the cytosol. Cytochrome c, binds to and activates APAF1 (apoptotic protease activating factor 1) in the cytosol by inducing a conformational change that allows APAF1 to bind to ATP/ dATP and to form an apoptosome, which mediates activa­tion of procaspase-9 and triggers activation of a procas­pase cascade.

      The extrinsic pathway starts with the binding of an extracellular death ligand, such as FasL, to its cell-surface death receptor, such as Fas. Binding of homotrimeric death ligands to their receptors leads to recruitment of cytosolic factors such as FADD (Fas-associated death domain) and caspase-8, forming an oligomeric death-inducing signaling complex (DISC). Formation of DISC leads to the activa­tion of the initiator caspase-8, which then cleaves and activates the effector procaspase-3. This pathway can crosstalk to the intrinsic cell death process through caspase-8-mediated cleavage of Bid, which then triggers the release of mitochondrial proteins [6-11].




Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006